SkinTE®would be the first new biologic commercially available in the U.S. for the treatment of a common chronic wound indication in nearly 30 years, if approved.SkinTE® is a first-in-class autologous ...
Wuxi, China, July 01, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: BYAH) (“Park Ha Biological” or the “Company”) announced that it has formally filed a complete ...
Preview this article 1 min Small-business grants available in July include a $20,000 option from Santander US and another grant possibility from Stanley. AI certifications can boost paychecks. But ...